Baxter International Inc.

BAX Healthcare Medical Instruments & Supplies

Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024. In the quarter to June 2026, revenue grew 5.34%, EPS grew 33.3%, free cash flow grew 119.5% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for three consecutive years.

25.33 0.43 −1.67%
Market cap
$13.3B
P/E
0.0×
Fwd P/E
44.7×
Dividend yield
0.16%
F-score
4/9
Altman Z
2.12
Beneish M
−2.67
Dividend safety
0/100

Baxter International Inc. (BAX) EBITDA

Alert me on EBITDA

Baxter International Inc.'s EBITDA for fiscal 2025 was $1.4B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.5B. Over the past ten years it has ranged from $1.2B (fiscal 2015) to $2.6B (fiscal 2019); the current reading is higher than 27% of that period. Baxter International Inc. ranks 7th of 50 Medical Instruments & Supplies companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 $1.4B (2.56%)
FY2024 $1.5B (12.12%)
FY2023 $1.7B 22.27%
FY2022 $1.4B (37.62%)
FY2021 $2.2B (9.73%)
FY2020 $2.5B (5.25%)
FY2019 $2.6B 10.06%
FY2018 $2.4B 15.55%
FY2017 $2.0B 31.91%
FY2016 $1.5B 27.90%

Quarterly newest first

Period EBITDA Change
Jun 2026 $456.0M 50.50%
Mar 2026 $303.0M 5.94%
Dec 2025 $286.0M (30.07%)
Sep 2025 $409.0M (8.71%)
42 more quarters

Against its own ten years

Low $1.2B High $2.6B
Ten-year median $1.7B
Current reading's percentile 27

EBITDA against peers

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on BAX